Endocyte, Inc.: Series C $15M

Endocyte (West Lafayette, IN) developer of folate-targeted based therapeutics for the treatment of renal cell carcinoma, ovarian, endometrial and nscl cancer raised $15M in a Series C financing. Participants included Sanderling Ventures, Burrill & Company, Triathlon Medical Ventures, Blue Chip Venture Company, American Bailey Ventures and CID Capital.

Transoma Medical, Inc.: Series C $13M

Transoma Medical (St. Paul, MN) maker of implantable wireless monitoring systems for patients with chronic cardiovascular disease closed a $13M Series C financing. The deal was led by Canaan Partners, Affinity Capital Management and Polaris Venture Partners.

NextWave Pharma, Inc.: Series B $40M

NextWave Pharma (Buffalo Grove, Ill) a pediatric drug company operating in stealth mode, closed $40M in Series B funding. The round was led by return investors Sofinnova Ventures and Vivo Ventures.

Semafore Pharmaceuticals Inc.: Series B $9.5M

Semafore Pharmaceuticals (Indianapolis, IN) a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway has raised $9.5M in Series B funding led by Twilight Venture Partners.

Softscope Medical Tech.: Series A $4M

Softscope Medical Technologies, Inc. (St. Louis Park, MN) an early stage medical device company developing improved endoscopic procedures, has completed a $4M Series A financing. The round was led by Thomas, McNerney & Partners and Accuitive Medical Ventures.